Advances in Drug Discovery 2017

Delegates have unrestricted access to all conference tracks and networking opportunities at this SELECTBIO multi-track event: Epigenetics in DD; Antibodies in DD; Academic DD; Stem Cells in DD.

Building on the success of our Cambridge Workshop Series, this SELECTBIO conference will feature four tracks: Epigenetics in Drug Discovery; Antibodies in Drug Discovery; Academic Drug Discovery; Stem Cells in Drug Discovery. Delegates have unrestricted access to all conference tracks and networking opportunities.

Epigenetics in Drug Discovery

This track will explore the latest opportunities and challenges for epigeneticists looking to discover and develop new molecular entities.

Topics to be addressed include, assays for Methyltranferases and Demethylases, Bromodomain inhibitor discovery, indications beyond cancer, Non-BET Bromodomains and of course updates in Oncology.

Antibodies in Drug Discovery

This track will fully explore the latest developments in the design and engineering of antibodies in relation to the burgeoning field of biotherapeutics.

Topics to be addressed include, engineering challenges and techniques, new technologies and business hurdles when developing antibodies, the latest developments in autoimmune and infectious disease research.

Academic Drug Discovery

Researchers, group leaders, directors and heads of leading academic and open innovation drug discovery centres will hear about the current challenges and opportunities faced in academic drug discovery.

Topics covered include Open Innovation, Successful Partnering Models for Academia and Industry, Fragment Based Drug Discovery, New Lead Identification, Lead Optimisation and Medicinal Chemistry.

Stem Cells in Drug Discovery

Hear from researchers currently screening for efficacy and toxicity using iPS cell lines, and those responsible for developing the techniques and technologies enabling them to do so. Industry and regulatory developments that are shaping the future of drug discovery will